Milademetan
- Generic Name
- Milademetan
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34Cl2FN5O4
- CAS Number
- 1398568-47-2
- Unique Ingredient Identifier
- R3I80TLN7S
- Background
Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)).
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
• Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
• FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer.
• Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
FDA Approves Daiichi Sankyo's Dato-DXd for Breast Cancer, Expanding Treatment Options
The FDA has granted approval for Daiichi Sankyo's Dato-DXd for breast cancer treatment, marking the drug's first US approval and second global authorization. This unexpected early approval strengthens the company's market position, with additional potential in non-small-cell lung cancer (NSCLC) treatment on the horizon.
Siremadlin Plus Ribociclib Shows Promise in MDM2/CDK4-Amplified Liposarcoma
• The combination of siremadlin and ribociclib demonstrates encouraging efficacy and a manageable safety profile in patients with advanced MDM2/CDK4-amplified liposarcoma.
• In a subset of liposarcoma patients, the combination therapy resulted in a median overall survival of 23 months, significantly longer than historical controls.
• The MEGAMOST trial suggests that targeting both MDM2 and CDK4/6 pathways may be a beneficial therapeutic approach in liposarcomas with specific genetic profiles.
• The study highlights the potential of molecularly driven treatment strategies to improve outcomes in advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath